United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

United Therapeutics (Nasdaq: UTHR), a public benefit , announced that Dr. Martine Rothblatt, Chairperson and CEO, will present an overview and update on the company's business at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

The presentation is scheduled for Monday, January 13, 2025, from 2:15 p.m. to 2:55 p.m., Pacific Standard Time. It will be accessible via a live webcast on the United Therapeutics website: United Therapeutics Webcast. An archived version will be available approximately 24 hours after the session ends and can be accessed for 30 days.

United Therapeutics, known for its innovative approaches to meeting unmet medical needs, is the first publicly-traded biotech or pharmaceutical company to become a public benefit (PBC). The company's mission includes developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a presentation at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco.

The presentation will take place on Monday, January 13, 2025, from 2:15 p.m. to 2:55 p.m., Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 30 days.

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/pbc.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of January 6, 2025, and assume no obligation to update or revise the information contained in this press release whether because of new information, future events or any other reason.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250106877038/en/

Dewey Steadman at (202) 919-4097 (media/investors)

Harry Silvers at (301) 578-1401 (investors)

https://ir.unither.com/contact-ir

Source: United Therapeutics Corporation

FAQ

When is United Therapeutics presenting at the J.P. Morgan Healthcare Conference?

United Therapeutics is presenting on Monday, January 13, 2025, from 2:15 p.m. to 2:55 p.m. PST.

How can I watch the United Therapeutics presentation at the J.P. Morgan Healthcare Conference?

You can watch the presentation via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations.

What topics will United Therapeutics cover in their J.P. Morgan Healthcare Conference presentation?

Dr. Martine Rothblatt will provide an overview and update on United Therapeutics' business.

How long will the recorded webcast of United Therapeutics' presentation be available?

The recorded webcast will be available approximately 24 hours after the session ends and accessible for 30 days.

What is the significance of United Therapeutics being a public benefit (PBC)?

As a PBC, United Therapeutics aims to provide a brighter future for patients through novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.